Frontiers in Drug Safety and Regulation

Policy and Practice Reviews

Accepted on 17 Nov 2025

Background Incidence Rates from Electronic Healthcare Databases for Vaccine Safety Monitoring: Review of Challenges from the COVID-19 Vaccination Campaign and Proposal for Best Practices

Sonja Banga
Laurence Serradell
Deborah Layton
Jill Dreyfus
Nicolas Praet
Diana C. Garofalo
Vincent Bauchau
Scott Kelly
Lin Li

Frontiers in Drug Safety and Regulation

Original Research

Published on 14 Nov 2025

Reporting rates of abnormal uterine bleeding after COVID-19 vaccination in South Korea

Jae Min Lee
Seung Geun Yeo
Sung Soo Kim
Dong Choon Park

Frontiers in Drug Safety and Regulation

doi 10.3389/fdsfr.2025.1658412

511 views

Correction

Published on 07 Nov 2025

Correction: Leveraging real-world data for safety signal detection and risk management in pre- and post-market settings

Kathleen M. Gavin
Matthew L. Sundermann
Alethea Wieland

Frontiers in Drug Safety and Regulation

doi 10.3389/fdsfr.2025.1729828

699 views

Review

Accepted on 05 Nov 2025

Pharmacovigilance and Bioethics: The Importance of a Neglected Relationship

Giuseppe Alvaro
Richa Chhibber
Robert Fuentes

Frontiers in Drug Safety and Regulation

395 views

Review

Accepted on 27 Oct 2025

Discrepancies in Regulations in Post-Marketing Safety Surveillance of Drug-Device Combination Products in the EU and US: a Review

Joan D'Souza
Mukesh Nandave
Ruth Blochlinger

Frontiers in Drug Safety and Regulation

444 views

Review

Accepted on 21 Oct 2025

The use of Observed-to-Expected analyses as a signal detection tool in COVID-19 vaccine safety surveillance: lessons learned from an industry perspective

LAURENCE SERRADELL
ANTONELLA FRETTA
JENNY NACHBAR
JILL DREYFUS
DIANA GAROFALO
ARIANNA LUCINI
SUSAN MATHER
DAINA ESPOSITO
ANNE-LAURE CHABANON
VINCENT BAUCHAU

Frontiers in Drug Safety and Regulation

363 views

Perspective

Published on 17 Oct 2025

Leveraging real-world data for safety signal detection and risk management in pre- and post-market settings

Kathleen M. Gavin
Matthew L. Sundermann
Alethea Wieland

Frontiers in Drug Safety and Regulation

doi 10.3389/fdsfr.2025.1626822

1,901 views

Perspective

Published on 16 Oct 2025

Communicating medication risks in pregnancy: Towards shared decision making

Ursula Winterfeld
Kenneth Hodson
Maya Berlin
Benoît Marin
Michael Ceulemans
Corinna Weber-Schoendorfer
François R. Girardin
David Baud
Béatrice Schaad
Alice Panchaud

Frontiers in Drug Safety and Regulation

doi 10.3389/fdsfr.2025.1712216

892 views

Policy and Practice Reviews

Accepted on 07 Oct 2025

Post-Approval Safety Studies of Vaccines in Pregnancy: Available Regulatory Guidance and Next Steps Towards the More Efficient Generation of Safety Evidence

Sarah C MacDonald
Adrienne Guignard
Flor M Munoz
Eileen Dareng
Kourtney Davis
Marina Amaral de Avila Machado
Shahar Shmuel
Laura Taddei
Lydie Marcelon

Frontiers in Drug Safety and Regulation

338 views

Perspective

Accepted on 03 Oct 2025

The Role of MedDRA in Global Pharmacovigilance and Public Health during COVID-19: Pandemic Preparedness and Response

Brian O’Hare
Heba Ibrahim
Patrick Revelle

Frontiers in Drug Safety and Regulation

222 views

Opinion

Published on 16 Sep 2025

Rethinking drug safety signal detection and causality assessment in the age of AI: the risks of incomplete data and biased insights

Priyanka Chhikara
Tarek A. Hammad

Frontiers in Drug Safety and Regulation

doi 10.3389/fdsfr.2025.1678074

2,510 views

Original Research

Published on 10 Sep 2025

Identifying regulatory outcomes of Non-interventional Post-Authorisation Safety Studies (PASS) in the European repository of studies using publicly available information

M. F. Almas
A. Girardi
S. Crisafulli
K. Gvozdanovic
K. M. Hakkarainen
G. Hyeraci
W. E. Hoogendoorn
B. Rillmann
G. Roberto
G. Vitturi

Frontiers in Drug Safety and Regulation

doi 10.3389/fdsfr.2025.1574430

1,692 views

Mini Review

Accepted on 25 Aug 2025

Tokenization Techniques for Privacy-Preserving Healthcare Data: Tokenization Nuts and Bolts

Camille Cook

Frontiers in Drug Safety and Regulation

712 views

Perspective

Published on 15 Aug 2025

A national pharmacovigilance centre perspective on pandemic preparedness - lessons learned from the COVID-19 pandemic

Florence van Hunsel
Agnes Kant

Frontiers in Drug Safety and Regulation

doi 10.3389/fdsfr.2025.1644680

3,166 views

Clinical Trial

Published on 11 Aug 2025

Medication beliefs and adherence during and after pregnancy among women at risk for gestational hypertensive disorders

Pauline Dreesen
Dorien Lanssens
Sandy Nouwen
Pauline Volders
Febe Janssen
Adelheid Soubry
Wilfried Gyselaers
Michael Ceulemans

Frontiers in Drug Safety and Regulation

doi 10.3389/fdsfr.2025.1610273

1,656 views

Editorial

Published on 28 Jul 2025

Editorial: Safety of corticosteroids in respiratory medicine

Semra Bilaçeroğlu

Frontiers in Drug Safety and Regulation

doi 10.3389/fdsfr.2025.1656299

1,614 views

95 Publications

Volume 5 - 2025

Background Incidence Rates from Electronic Healthcare Databases for Vaccine Safety Monitoring: Review of Challenges from the COVID-19 Vaccination Campaign and Proposal for Best Practices

Reporting rates of abnormal uterine bleeding after COVID-19 vaccination in South Korea

Correction: Leveraging real-world data for safety signal detection and risk management in pre- and post-market settings

Pharmacovigilance and Bioethics: The Importance of a Neglected Relationship

Discrepancies in Regulations in Post-Marketing Safety Surveillance of Drug-Device Combination Products in the EU and US: a Review

The use of Observed-to-Expected analyses as a signal detection tool in COVID-19 vaccine safety surveillance: lessons learned from an industry perspective

Leveraging real-world data for safety signal detection and risk management in pre- and post-market settings

Communicating medication risks in pregnancy: Towards shared decision making

Post-Approval Safety Studies of Vaccines in Pregnancy: Available Regulatory Guidance and Next Steps Towards the More Efficient Generation of Safety Evidence

The Role of MedDRA in Global Pharmacovigilance and Public Health during COVID-19: Pandemic Preparedness and Response

Rethinking drug safety signal detection and causality assessment in the age of AI: the risks of incomplete data and biased insights

Identifying regulatory outcomes of Non-interventional Post-Authorisation Safety Studies (PASS) in the European repository of studies using publicly available information

Tokenization Techniques for Privacy-Preserving Healthcare Data: Tokenization Nuts and Bolts

A national pharmacovigilance centre perspective on pandemic preparedness - lessons learned from the COVID-19 pandemic

Medication beliefs and adherence during and after pregnancy among women at risk for gestational hypertensive disorders

Editorial: Safety of corticosteroids in respiratory medicine